Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Neovascular AMD (Genotype and Environment)
NCT00469352Phase 3Completed
- Sponsor
- Oregon Health & Science University
- Start
- May 2007
- Primary completion
- Apr 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranibizumab in exudative macular degeneration, sponsored by Oregon Health & Science University. Primary endpoint: Clinical treatment response to intravitreal Lucentis at 12 months. Started May 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00469352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469352.